Analgosedation in a Patient Whose Baseline Opioid Dose Isn't a Starting Point
His home methadone dose alone exceeds what most post-surgical patients receive for actual pain. Standard weight-based ICU opioid dosing would leave him both under-treated for surgical pain and in withdrawal at the same time.
D.V., a 44-year-old man, has been on methadone maintenance 90 mg daily for eleven years following a structured recovery from opioid use disorder, and is now two days post-op from an open reduction and internal fixation of a tibial plateau fracture after a construction-site fall. He is careful about how he talks about opioids at all, and admits he nearly didn't mention the methadone dose to the covering team on admission for fear of how it would be read — which turns out not to be what went wrong, because he did tell them. His pain team notes, almost as an aside in the consult, that his methadone alone represents a baseline tolerance well above what most post-surgical patients ever receive for acute pain, a line the covering ICU team had not registered when it wrote his post-operative orders on the unit's standard weight-based protocol and held his home methadone. He is reporting 8 out of 10 on a running hydromorphone PCA, diaphoretic and restless: under-treated and in withdrawal simultaneously, from one wrong assumption at intake rather than anything he failed to disclose.
That standard protocol assumes an opioid-naive starting point, and applying it to him directly under-doses his acute surgical pain while risking withdrawal if his home methadone isn't continued as its own separate, protected baseline — two distinct failures stacked on top of each other, not one problem correctable by scaling up a single number. Alford, Compton and Samet set out the four misconceptions that produce exactly the orders he is currently on, and the load-bearing one is the belief that maintenance methadone supplies any acute analgesia at all: at 90 mg once daily it occupies his tolerance and does nothing for a fractured tibial plateau. His requirement is a preserved baseline plus separately-dosed acute coverage, and Athanasos's work is why that second number has to be large — methadone-maintained patients proved cross-tolerant to the antinociceptive effect of morphine even at plasma concentrations that would be dangerous in anyone opioid-naive. Which is also where opioid-induced hyperalgesia stops being a textbook aside and becomes his particular hazard: the dose that finally reaches him sits inside the range where further escalation can worsen pain sensitivity rather than relieve it.
Pain team consult, post-operative day 2
The first fix is structural, not a dose adjustment — resume his home methadone 90 mg daily as its own fixed, protected baseline immediately, and calculate acute surgical-pain coverage as a genuinely separate, additive layer on top of it. The standard weight-based protocol he's currently on assumes an opioid-naive starting point that simply doesn't describe him; both his withdrawal signs and his under-treated pain trace back to that mismatch.
Restore the baseline, yes — but I'd push back on the additive model you've just described. If Athanasos is right that he's cross-tolerant even at very high plasma opioid concentrations, then "baseline plus a bigger acute layer" may be chasing a receptor population that won't answer at any dose we're actually willing to give. That argues for a regional technique as his primary analgesic rather than an adjunct bolted onto an opioid plan — an adductor canal or popliteal block doesn't care about his mu-receptor tolerance. Ketamine for the same reason, and started now, not held as rescue for after the opioid strategy has failed him a second time.
Both of those are right, and I'd add one practical caution: the far more common real-world failure with patients like him isn't over-treatment, it's clinicians pulling back out of anxiety about "feeding" his tolerance, which leaves him simultaneously in pain and in functional withdrawal — exactly the state he's in right now. Treat to his actual, objectively scored analgesic need, not to a number that feels uncomfortably high on the chart.
Agreed: home methadone resumed as a protected baseline, hydromorphone PCA continued as a genuinely additive acute-pain layer with dosing titrated to objective pain scores rather than capped by discomfort with the total number, and ketamine infusion started to limit further opioid escalation. His withdrawal signs resolved within hours and his reported pain scores improved to a consistent 3-4/10 over the following day.
The team documented the corrected dosing structure explicitly in his chart, specifically so a future covering team wouldn't repeat the original opioid-naive-protocol mismatch if he required further surgical care during this same hospitalization.